Pancreatic Cancer Research

Clinical trialPhase 1Completed

ORB-011 In Patients With Advanced Solid Tumors

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
21 August 2023
Ended
29 May 2026
Enrollment
55 participants
Sites
2
Primary outcomes
Number of Adverse Events (AE) in patients dosed with ORB-011; Determine Recommended Phase 2 Dose (RP2D)
Sponsor type
Industry
Results posted
No
Last update
12 June 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.

Detailed description public domain (ClinicalTrials.gov)

ORB-011 is a complex engineered biologic molecule that targets interferon alpha 2b activation specifically to type 1 conventional dendritic cells (cDC1). The interferon alpha 2b in ORB-011 is inactive to all other cell types but confers full activation in cis when bound to cDC1 cells which exclusively express CLEC9a, thereby eliminating the potential systemic toxicities caused by alpha interferon when binding to interferon receptors on other cells. ORB-1 is administered by intravenous (IV) infusion. In cancer patients, treatment may be repeated every 3 weeks.